The Unique Properties of Placental Mesenchymal Stromal Cells: A Novel Source of Therapy for Congenital and Acquired Spinal Cord Injury.
Edwin S KulubyaKaitlin ClarkDake HaoSabrina Valentina LazarArash Ghaffari-RafiTejas KarnatiJulius Okudu EbinuMarike ZwienenbergDiana L FarmerAijun WangPublished in: Cells (2021)
Spinal cord injury (SCI) is a devasting condition with no reliable treatment. Spina bifida is the most common cause of congenital SCI. Cell-based therapies using mesenchymal stem/stromal cells (MSCS) have been largely utilized in SCI. Several clinical trials for acquired SCI use adult tissue-derived MSC sources, including bone-marrow, adipose, and umbilical cord tissues. The first stem/stromal cell clinical trial for spina bifida is currently underway (NCT04652908). The trial uses early gestational placental-derived mesenchymal stem/stromal cells (PMSCs) during the fetal repair of myelomeningocele. PMSCs have been shown to exhibit unique neuroprotective, angiogenic, and antioxidant properties, all which are promising applications for SCI. This review will summarize the unique properties and current applications of PMSCs and discuss their therapeutic role for acquired SCI.
Keyphrases
- spinal cord injury
- bone marrow
- clinical trial
- mesenchymal stem cells
- umbilical cord
- spinal cord
- neuropathic pain
- cell therapy
- phase ii
- single cell
- study protocol
- stem cells
- phase iii
- gene expression
- pregnant women
- open label
- oxidative stress
- weight gain
- adipose tissue
- randomized controlled trial
- type diabetes
- drinking water
- skeletal muscle
- double blind
- smoking cessation
- metabolic syndrome
- weight loss
- preterm birth
- young adults
- brain injury
- blood brain barrier
- pregnancy outcomes
- childhood cancer
- gestational age